摘要
目前,世界范围内结核病仍是广泛流行的重要传染病,多重耐药结核分枝杆菌的出现和艾滋病合并结核感染的致死性协同作用使得这种情况雪上加霜。因此,临床渴求新的抗痨药物以满足耐药结核治疗的需求。现主要对喹啉类、硝基咪唑吡喃类、噁唑烷酮类、吡咯类等新合成的抗结核药物作综述。
At present, Tuberculosis （TB） is still a common cause of death worldwide. The situation is getting worse and worse with the emergence of multidrug-resistant TB （MDR-TB） and the infection＇s lethal synergy withHIV/AIDS. For this reason, all the clinicians are now pleading for new drug interventions that can address these unmet needs in resistant TB treatment. In this review article, some new composite antituberculosis agents such as quinolines, nitroimidazopyrans, ephedroxanes, pyrroles and so on are briefly infroduced.
出处
《预防医学情报杂志》
CAS
2009年第2期130-133,共4页
Journal of Preventive Medicine Information
关键词
结核
结核分枝杆菌
抗结核药物
Tuberculosis
Mycobacterium tuberculosis
Antituberculosis agent
